slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,471
Current window 48,961-48,990
Pages 3,683
Rows per page 30
Component
48,961-48,990 of 110,471
01
The slide serves as a cover or introductory page for a survey report.2018 Manufacturing Priorities Survey · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
03
The chart uses a 1-7 Likert scale to compare mean responses across three survey questions.2018 Manufacturing Priorities Survey · L.E.K.
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
04
The chart is a diverging bar chart showing 'No' vs 'Yes' responses, with a calculated 'Difference' column.2018 Manufacturing Priorities Survey · L.E.K.
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
05
The slide uses a horizontal bar chart to rank strategic priorities based on survey responses.2018 Manufacturing Priorities Survey · L.E.K.
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
08
The slide highlights that the shift is moving from traditional customer-facing roles to internal operational departments.2018 Manufacturing Priorities Survey · L.E.K.
Consulting deck Strategy consulting Beat · Evidence & Proof1 hit
13
Includes L.E.K. Consulting firm boilerplate and copyright information.2018 Manufacturing Priorities Survey · L.E.K.
Consulting deck Strategy consulting 1 hit
03
Includes a list of representative titles and company logos.2022 Manufacturing Survey · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
02
2023 Manufacturing Survey2023 Manufacturing Survey · L.E.K.
Consulting deck Strategy consulting Beat · ProblemLoop · Logic Chain1 hit
06
The slide uses a ranking system (1-8) to compare priorities across two time horizons.2023 Manufacturing Survey · L.E.K.
Consulting deck Strategy consulting Beat · SolutionLoop · Logic Chain1 hit
08
The chart is split into two groups: 'Lowest increase in long-term confidence' (left) and 'Highest increase in long-term confidence' (right).2023 Manufacturing Survey · L.E.K.
Consulting deck Strategy consulting Beat · SolutionLoop · Logic Chain1 hit
10
The slide uses a color-coded key to distinguish between Financial, Transformative, and Operational initiatives.2023 Manufacturing Survey · L.E.K.
Consulting deck Strategy consulting Beat · Solution1 hit
12
2023 Manufacturing Survey2023 Manufacturing Survey · L.E.K.
Consulting deck Strategy consulting 1 hit
02
APAC Hospital Insights 2023APAC Hospital Insights 2023 · LEK
Consulting deck Strategy consulting 1 hit
10
Data refers to enterprises above designated annual revenue size (>20M RMB). Exchange rate 6.25 used.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
13
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
14
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
15
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
17
The chart displays 4 categories of FDA designations with stacked segments representing product types.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
23
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
29
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
38
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
40
Survey data from IQVIA/L.E.K. Consulting (N=56).Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
45
The slide highlights a strategic shift in MNC R&D presence in China, moving towards collaborative incubation models.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
47
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
49
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
50
The slide presents qualitative interview profiles and quantitative survey respondent demographics.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
53
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
57
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
06
The slide uses a bar chart to visualize market growth and a callout box to highlight the projected market value.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
15
The slide uses a two-column layout with icons for each service offering.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Quick Win Big Bet1 hit